Monika Kałwak
Research Subjects
Monika Kałwak has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Foryś
Provincial Specialist Hospital No. 5 of St. Barbara in Sosnowiec, Sosnowiec, Poland
11 shared publications - Cezary Orzechowski
Medical University of Warsaw, Warsaw, Poland
6 shared publications - Justyna Żabicka
Maria Skłodowska-Curie Warsaw Higher School, Warsaw, Poland
6 shared publications - Kinga Lichtarska
Lazarski University, Warsaw, Poland
6 shared publications - Magda Marciniak
Specialist Hospital of Dr. Tytus Chałubiński in Radom, Radom, Poland
6 shared publications - Michał Gutowski
Medical University of Warsaw, Warsaw, Poland
6 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Medical Education in OphthaTherapy. Therapies in Ophthalmology
- p. A1109
The effect of hemodialysis on intraocular pressure and ocular perfusion pressure: an interdisciplinary review
Hemodialysis, as the most commonly used method of renal replacement therapy, may induce changes in intraocular pressure. A hemodialysis-associated increase in intraocular pressure has been reported primarily in patients with impaired aqueous humor outflow, including those with narrow or closed iridocorneal angles and those with primary or secondary glaucoma, especially neovascular or pseudoexfoliative glaucoma. One of the main mechanisms underlying intraocular pressure elevation is considered to be a non-synchronous decrease in blood and intraocular fluid osmolality, leading to a transient osmotic gradient and fluid shift into the eyeball. Hemodialysis may also affect ocular perfusion pressure, and its reduction may increase optic nerve susceptibility to damage even when intraocular pressure remains within normal limits. Fluctuations in both intraocular pressure and ocular perfusion pressure represent a clinically significant but under recognized concern in patients at risk. This review highlights the importance of interdisciplinary collaboration between nephrologists and ophthalmologists, while existing knowledge gaps justify further research in this area.
- 18 September 2026
- Published by Medical Education in OphthaTherapy. Therapies in Ophthalmology
- p. A1109
Open AccessThe effect of hemodialysis on intraocular pressure and ocular perfusion pressure: an interdisciplinary review
Hemodialysis, as the most commonly used method of renal replacement therapy, may induce changes in intraocular pressure. A hemodialysis-associated increase in intraocular pressure has been reported primarily in patients with impaired aqueous humor outflow, including those with narrow or closed iridocorneal angles and those with primary or secondary glaucoma, especially neovascular or pseudoexfoliative glaucoma. One of the main mechanisms underlying intraocular pressure elevation is considered to be a non-synchronous decrease in blood and intraocular fluid osmolality, leading to a transient osmotic gradient and fluid shift into the eyeball. Hemodialysis may also affect ocular perfusion pressure, and its reduction may increase optic nerve susceptibility to damage even when intraocular pressure remains within normal limits. Fluctuations in both intraocular pressure and ocular perfusion pressure represent a clinically significant but under recognized concern in patients at risk. This review highlights the importance of interdisciplinary collaboration between nephrologists and ophthalmologists, while existing knowledge gaps justify further research in this area.
- Open Access
- 11 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 73808
Selected Cutaneous and Mucocutaneous Manifestations Associated with Inflammatory Bowel Disease: Diagnostic and Therapeutic Implications
Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, comprises chronic inflammatory disorders of the gastrointestinal tract. In addition to intestinal symptoms, IBD may be accompanied by numerous extraintestinal manifestations, including cutaneous and mucocutaneous lesions. The most commonly reported dermatological manifestations include erythema nodosum, pyoderma gangrenosum, and oral lesions associated with Crohn’s disease. Cutaneous manifestations may precede the diagnosis of IBD; therefore, their recognition is important not only for dermatologists, but also for specialists in internal medicine and gastroenterology. Early identification of these manifestations may contribute to earlier diagnosis of the underlying disease and implementation of appropriate treatment. This review discusses selected, clinically relevant cutaneous and mucocutaneous manifestations in the course of IBD, with particular emphasis on their epidemiology, diagnostic criteria, clinical presentation, and therapeutic options.
- 11 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 95, 73808
Open AccessSelected Cutaneous and Mucocutaneous Manifestations Associated with Inflammatory Bowel Disease: Diagnostic and Therapeutic Implications
Inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, comprises chronic inflammatory disorders of the gastrointestinal tract. In addition to intestinal symptoms, IBD may be accompanied by numerous extraintestinal manifestations, including cutaneous and mucocutaneous lesions. The most commonly reported dermatological manifestations include erythema nodosum, pyoderma gangrenosum, and oral lesions associated with Crohn’s disease. Cutaneous manifestations may precede the diagnosis of IBD; therefore, their recognition is important not only for dermatologists, but also for specialists in internal medicine and gastroenterology. Early identification of these manifestations may contribute to earlier diagnosis of the underlying disease and implementation of appropriate treatment. This review discusses selected, clinically relevant cutaneous and mucocutaneous manifestations in the course of IBD, with particular emphasis on their epidemiology, diagnostic criteria, clinical presentation, and therapeutic options.
- Open Access
- 2 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
RETHINKING PRIMARY SPONTANEOUS PNEUMOTHORAX IN CHILDREN AND ADOLESCENTS: CURRENT EVIDENCE AND EVOLVING MANAGEMENT STRATEGIES
Primary spontaneous pneumothorax (PSP) is increasingly identified in adolescents, but its management is still debated due to a lack of robust pediatric data and a reliance on adult guidelines. As a result, pediatric centers show significant differences in their approaches to diagnosis, imaging, treatment decisions, surgical timing, and follow-up care. This review outlines the latest evidence on diagnosing and managing pediatric primary spontaneous pneumothorax (PSP). Current research favors a symptom-based diagnostic method, with chest X-rays serving as the primary imaging tool. Routine CT scans are discouraged because they expose children to unnecessary radiation, rarely change initial treatment plans, and fail to reliably predict recurrence based on radiographic blebs. Ultimately, treatment strategies should be customized based on the patient's clinical stability rather than relying solely on the size of the pneumothorax. Observation is a suitable approach for certain stable patients with small to moderate PSP. Conversely, treatments such as needle aspiration, chest tube drainage, or surgery should be utilized only for patients experiencing severe symptoms, continuous air leaks, unsuccessful lung re-expansion, or recurring pneumothorax. When surgical intervention is required, video-assisted thoracoscopic surgery is the favored method, though post-operative recurrence rates are higher in children compared to adults. Current evidence indicates a lack of standardized follow-up procedures for pediatric patients. Therefore, follow-up care should center on the early detection of recurrences, which typically happen within the first year of the initial event. The use of routine computed tomography for follow-up is not recommended. Additionally, patient counseling needs to address smoking and vaping cessation, guidelines for resuming physical activity, postponing air travel until imaging shows complete healing, and avoiding compressed-air diving due to a lifelong recurrence risk. Although recent progress has been made, significant knowledge gaps persist concerning the ideal selection of patients for conservative rather than surgical treatment, risk factors for recurrence, uniform follow-up protocols, and long-term results. To develop evidence-based, child-specific guidelines for diagnosing and treating primary spontaneous pneumothorax, future prospective multicenter pediatric studies are essential.
- 2 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessRETHINKING PRIMARY SPONTANEOUS PNEUMOTHORAX IN CHILDREN AND ADOLESCENTS: CURRENT EVIDENCE AND EVOLVING MANAGEMENT STRATEGIES
Primary spontaneous pneumothorax (PSP) is increasingly identified in adolescents, but its management is still debated due to a lack of robust pediatric data and a reliance on adult guidelines. As a result, pediatric centers show significant differences in their approaches to diagnosis, imaging, treatment decisions, surgical timing, and follow-up care. This review outlines the latest evidence on diagnosing and managing pediatric primary spontaneous pneumothorax (PSP). Current research favors a symptom-based diagnostic method, with chest X-rays serving as the primary imaging tool. Routine CT scans are discouraged because they expose children to unnecessary radiation, rarely change initial treatment plans, and fail to reliably predict recurrence based on radiographic blebs. Ultimately, treatment strategies should be customized based on the patient's clinical stability rather than relying solely on the size of the pneumothorax. Observation is a suitable approach for certain stable patients with small to moderate PSP. Conversely, treatments such as needle aspiration, chest tube drainage, or surgery should be utilized only for patients experiencing severe symptoms, continuous air leaks, unsuccessful lung re-expansion, or recurring pneumothorax. When surgical intervention is required, video-assisted thoracoscopic surgery is the favored method, though post-operative recurrence rates are higher in children compared to adults. Current evidence indicates a lack of standardized follow-up procedures for pediatric patients. Therefore, follow-up care should center on the early detection of recurrences, which typically happen within the first year of the initial event. The use of routine computed tomography for follow-up is not recommended. Additionally, patient counseling needs to address smoking and vaping cessation, guidelines for resuming physical activity, postponing air travel until imaging shows complete healing, and avoiding compressed-air diving due to a lifelong recurrence risk. Although recent progress has been made, significant knowledge gaps persist concerning the ideal selection of patients for conservative rather than surgical treatment, risk factors for recurrence, uniform follow-up protocols, and long-term results. To develop evidence-based, child-specific guidelines for diagnosing and treating primary spontaneous pneumothorax, future prospective multicenter pediatric studies are essential.
- Open Access
- 28 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
VITAMIN D STATUS AND ITS IMPACT ON DISEASE ACTIVITY IN PEDIATRIC-ONSET MULTIPLE SCLEROSIS: A COMPREHENSIVE NARRATIVE REVIEW
Pediatric-onset multiple sclerosis (POMS), defined as the onset of multiple sclerosis (MS) before the age of 18 years, accounts for approximately 3–5% of all MS cases and is characterized by a markedly inflammatory disease course with high relapse rates and earlier accrual of cognitive and physical disability than adult-onset disease [22–25]. Among the modifiable environmental risk factors implicated in MS susceptibility and activity, vitamin D has attracted sustained scientific attention [3,4,48]. This narrative review synthesizes current evidence on the role of vitamin D in POMS, integrating epidemiological, immunological, genetic (Mendelian randomization), observational and interventional data. Mendelian randomization analyses provide robust evidence for a causal relationship between genetically lowered 25-hydroxyvitamin D [25(OH)D] concentrations and increased POMS susceptibility (OR 0.72, 95% CI 0.55–0.94, p = 0.02 for higher genetically predicted vitamin D) [1]. Observational studies consistently report that each 10 ng/mL (25 nmol/L) increase in serum 25(OH)D is associated with an approximately 34% reduction in subsequent relapse rate in POMS [2], and with comparable reductions in new T2 and gadolinium-enhancing magnetic resonance imaging (MRI) lesions in mixed adult-pediatric cohorts [17,19]. Despite biologically plausible immunomodulatory and remyelinating effects demonstrated in experimental models [36–39], randomized controlled trials of vitamin D supplementation have predominantly failed to meet primary clinical endpoints, with positive signals largely confined to secondary MRI outcomes [5,6,41–43]. Pediatric-specific randomized data remain scarce. Current expert consensus supports avoidance of insufficiency (25(OH)D < 20 ng/mL) and targeting serum levels of 30–50 ng/mL (75–125 nmol/L) using daily doses up to 2000–4000 IU of cholecalciferol, with biochemical monitoring [3,27,28,50]. Future research priorities include adequately powered pediatric trials, harmonized dosing protocols, and long-term safety surveillance.
- 28 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessVITAMIN D STATUS AND ITS IMPACT ON DISEASE ACTIVITY IN PEDIATRIC-ONSET MULTIPLE SCLEROSIS: A COMPREHENSIVE NARRATIVE REVIEW
Pediatric-onset multiple sclerosis (POMS), defined as the onset of multiple sclerosis (MS) before the age of 18 years, accounts for approximately 3–5% of all MS cases and is characterized by a markedly inflammatory disease course with high relapse rates and earlier accrual of cognitive and physical disability than adult-onset disease [22–25]. Among the modifiable environmental risk factors implicated in MS susceptibility and activity, vitamin D has attracted sustained scientific attention [3,4,48]. This narrative review synthesizes current evidence on the role of vitamin D in POMS, integrating epidemiological, immunological, genetic (Mendelian randomization), observational and interventional data. Mendelian randomization analyses provide robust evidence for a causal relationship between genetically lowered 25-hydroxyvitamin D [25(OH)D] concentrations and increased POMS susceptibility (OR 0.72, 95% CI 0.55–0.94, p = 0.02 for higher genetically predicted vitamin D) [1]. Observational studies consistently report that each 10 ng/mL (25 nmol/L) increase in serum 25(OH)D is associated with an approximately 34% reduction in subsequent relapse rate in POMS [2], and with comparable reductions in new T2 and gadolinium-enhancing magnetic resonance imaging (MRI) lesions in mixed adult-pediatric cohorts [17,19]. Despite biologically plausible immunomodulatory and remyelinating effects demonstrated in experimental models [36–39], randomized controlled trials of vitamin D supplementation have predominantly failed to meet primary clinical endpoints, with positive signals largely confined to secondary MRI outcomes [5,6,41–43]. Pediatric-specific randomized data remain scarce. Current expert consensus supports avoidance of insufficiency (25(OH)D < 20 ng/mL) and targeting serum levels of 30–50 ng/mL (75–125 nmol/L) using daily doses up to 2000–4000 IU of cholecalciferol, with biochemical monitoring [3,27,28,50]. Future research priorities include adequately powered pediatric trials, harmonized dosing protocols, and long-term safety surveillance.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
RHINITIS MEDICAMENTOSA: PATHOPHYSIOLOGY, CLINICAL MANIFESTATIONS, AND CURRENT MANAGEMENTS STRATEGIES
Background: Rhinitis medicamentosa (RM) is a non-allergic condition caused by the prolonged use of topical nasal decongestants. Despite its prevalence, it remains frequently underdiagnosed in clinical practice. Objectives: This review synthesizes current knowledge on the pathophysiology, diagnostic criteria, and multifaceted treatment approaches for RM. Methods: A comprehensive literature search was conducted across PubMed (up to 2026) focusing on alpha-adrenergic agonist-induced mucosal changes and therapeutic interventions. Results: Chronic administration of sympathomimetics, such as xylometazoline, leads to adrenoceptor downregulation, secondary vasodilation, and permanent mucosal remodelling. Clinical presentation is characterized by rebound congestion and tachyphylaxis. Management centers on immediate or tapered decongestant cessation, supplemented by intranasal corticosteroids. In refractory cases involving turbinate hypertrophy, surgical intervention (e.g., conchoplasty) remains a definitive option. Conclusions: RM represents a significant clinical challenge. Increasing clinical awareness and patient education regarding the risk of decongestant overuse are crucial for prevention and successful long-term outcomes.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessRHINITIS MEDICAMENTOSA: PATHOPHYSIOLOGY, CLINICAL MANIFESTATIONS, AND CURRENT MANAGEMENTS STRATEGIES
Background: Rhinitis medicamentosa (RM) is a non-allergic condition caused by the prolonged use of topical nasal decongestants. Despite its prevalence, it remains frequently underdiagnosed in clinical practice. Objectives: This review synthesizes current knowledge on the pathophysiology, diagnostic criteria, and multifaceted treatment approaches for RM. Methods: A comprehensive literature search was conducted across PubMed (up to 2026) focusing on alpha-adrenergic agonist-induced mucosal changes and therapeutic interventions. Results: Chronic administration of sympathomimetics, such as xylometazoline, leads to adrenoceptor downregulation, secondary vasodilation, and permanent mucosal remodelling. Clinical presentation is characterized by rebound congestion and tachyphylaxis. Management centers on immediate or tapered decongestant cessation, supplemented by intranasal corticosteroids. In refractory cases involving turbinate hypertrophy, surgical intervention (e.g., conchoplasty) remains a definitive option. Conclusions: RM represents a significant clinical challenge. Increasing clinical awareness and patient education regarding the risk of decongestant overuse are crucial for prevention and successful long-term outcomes.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
ATOPIC DERMATITIS: FROM PATHOGENESIS TO TARGETED THERAPEUTIC STRATEGIES
Atopic dermatitis (AD), also referred to as atopic eczema, is a common chronic inflammatory skin disorder characterized by intense pruritus, xerosis, and recurrent eczematous lesions. It significantly affects patients’ quality of life and poses a considerable clinical burden. This review aims to summarize current knowledge on the pathogenesis of AD and highlight recent advances in targeted therapeutic strategies. A narrative review of recent literature was conducted, focusing on immunological pathways and modern treatment approaches. The analysis emphasizes the central role of immune dysregulation, particularly involving type 2 helper T-cell responses, impaired skin barrier function associated with filaggrin deficiency, and genetic predisposition in disease development. Environmental factors and microbiome alterations also contribute to disease exacerbation. Recent therapeutic progress has introduced targeted treatments, including biologic agents and Janus kinase inhibitors, which have demonstrated high efficacy and safety profiles. These innovations have significantly improved disease control and patient outcomes. In conclusion, improved understanding of AD pathogenesis supports the development of personalized and more effective management strategies.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
Open AccessATOPIC DERMATITIS: FROM PATHOGENESIS TO TARGETED THERAPEUTIC STRATEGIES
Atopic dermatitis (AD), also referred to as atopic eczema, is a common chronic inflammatory skin disorder characterized by intense pruritus, xerosis, and recurrent eczematous lesions. It significantly affects patients’ quality of life and poses a considerable clinical burden. This review aims to summarize current knowledge on the pathogenesis of AD and highlight recent advances in targeted therapeutic strategies. A narrative review of recent literature was conducted, focusing on immunological pathways and modern treatment approaches. The analysis emphasizes the central role of immune dysregulation, particularly involving type 2 helper T-cell responses, impaired skin barrier function associated with filaggrin deficiency, and genetic predisposition in disease development. Environmental factors and microbiome alterations also contribute to disease exacerbation. Recent therapeutic progress has introduced targeted treatments, including biologic agents and Janus kinase inhibitors, which have demonstrated high efficacy and safety profiles. These innovations have significantly improved disease control and patient outcomes. In conclusion, improved understanding of AD pathogenesis supports the development of personalized and more effective management strategies.
- 28 February 2026
- Published by European Scientific Society in Archiv Euromedica
- Vol. 16 (1)
Polycystic Ovary Syndrome in modern medicine: From etiology to diagnosis and evidence-based management
Background Polycystic ovary syndrome is one of the most common endocrine disorders in women of reproductive age and is associated with reproductive dysfunction, metabolic disturbances, and significant psychological burden. The marked heterogeneity of clinical phenotypes and variability in diagnostic criteria complicate timely diagnosis, risk stratification, and long-term management, underscoring the need for an integrated and clinically oriented synthesis of current evidence. Aims The aim of this narrative review is to summarize and integrate contemporary evidence on the epidemiology, pathophysiology, diagnostic approaches, and management of polycystic ovary syndrome, with particular emphasis on the interrelation of reproductive, metabolic, and psychological aspects relevant to clinical practice. Methods A narrative review of the literature was conducted using the PubMed, Google Scholar, and ResearchGate databases. International clinical guidelines, consensus documents, systematic reviews, meta-analyses, randomized controlled trials, cohort and population-based studies, and clinically relevant review articles were considered. The analysis was descriptive in nature and did not involve a formal systematic review protocol or quantitative data synthesis. Results The reviewed evidence confirms that polycystic ovary syndrome should be regarded as a chronic, multisystem condition rather than a disorder limited to reproductive age. Insulin resistance, hormonal dysregulation, and metabolic abnormalities contribute to long term risks, including infertility, type 2 diabetes mellitus, cardiovascular disease, endometrial pathology, and impaired quality of life. Phenotypic heterogeneity and inconsistent application of diagnostic criteria remain major barriers to early diagnosis and individualized management. Lifestyle modification represents the cornerstone of therapy across phenotypes, while pharmacological and fertility directed interventions should be tailored to individual clinical profiles. Psychological comorbidities are common and frequently underrecognized. Conclusions Effective management of polycystic ovary syndrome requires a patient centred and multidisciplinary approach that integrates reproductive, metabolic, and psychological care. Early identification of metabolic risk factors, long term follow up, and systematic attention to mental health are essential to improve clinical outcomes and quality of life.
- 28 February 2026
- Published by European Scientific Society in Archiv Euromedica
- Vol. 16 (1)
Polycystic Ovary Syndrome in modern medicine: From etiology to diagnosis and evidence-based management
Background Polycystic ovary syndrome is one of the most common endocrine disorders in women of reproductive age and is associated with reproductive dysfunction, metabolic disturbances, and significant psychological burden. The marked heterogeneity of clinical phenotypes and variability in diagnostic criteria complicate timely diagnosis, risk stratification, and long-term management, underscoring the need for an integrated and clinically oriented synthesis of current evidence. Aims The aim of this narrative review is to summarize and integrate contemporary evidence on the epidemiology, pathophysiology, diagnostic approaches, and management of polycystic ovary syndrome, with particular emphasis on the interrelation of reproductive, metabolic, and psychological aspects relevant to clinical practice. Methods A narrative review of the literature was conducted using the PubMed, Google Scholar, and ResearchGate databases. International clinical guidelines, consensus documents, systematic reviews, meta-analyses, randomized controlled trials, cohort and population-based studies, and clinically relevant review articles were considered. The analysis was descriptive in nature and did not involve a formal systematic review protocol or quantitative data synthesis. Results The reviewed evidence confirms that polycystic ovary syndrome should be regarded as a chronic, multisystem condition rather than a disorder limited to reproductive age. Insulin resistance, hormonal dysregulation, and metabolic abnormalities contribute to long term risks, including infertility, type 2 diabetes mellitus, cardiovascular disease, endometrial pathology, and impaired quality of life. Phenotypic heterogeneity and inconsistent application of diagnostic criteria remain major barriers to early diagnosis and individualized management. Lifestyle modification represents the cornerstone of therapy across phenotypes, while pharmacological and fertility directed interventions should be tailored to individual clinical profiles. Psychological comorbidities are common and frequently underrecognized. Conclusions Effective management of polycystic ovary syndrome requires a patient centred and multidisciplinary approach that integrates reproductive, metabolic, and psychological care. Early identification of metabolic risk factors, long term follow up, and systematic attention to mental health are essential to improve clinical outcomes and quality of life.
- Open Access
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
KETAMINE IN PAIN MANAGEMENT AND PSYCHIATRIC TREATMENT: CURRENT KNOWLEDGE AND IMPLICATIONS FOR CLINICAL PRACTICE
Research objectives: Ketamine, a derivative of phencyclidine, is a dissociative anesthetic that is used not only in anesthesia but also in analgesic and psychiatric settings such as perioperative and chronic pain, opioid-induced hyperalgesia and treatment-resistant depression management. With the general population’s prevalence of 2-40% for chronic pain and similar lifetime values for depression, ketamine deserves attention as an alternative to commonly used treatments. This research describes the use of subanesthetic ( 0,3 mg/kg to 0,5 mg/kg) ketamine doses in pain management and psychiatric settings, discusses its safety concerning psychomimetic and physical adverse effects and dependence risk, and suggests future research directions. Methods: Review of literature including peer-reviewed studies, meta-analyses, randomized controlled trials, clinical guidelines, focusing on ketamine pharmacokinetics, anesthetic and antidepressant effects, safety and clinical applications. Findings: Ketamine produces satisfactory short-term pain alleviation and rapid antidepressant action. It is part of multimodal anesthesia protocols as an adjuvant to other local anesthetics, prolonging their effects, and is a safe alternative for analgesia in opioid-tolerant patients. It has many routes of administration, which is used in patients with difficult intravenous access in emergencies. It provides a beneficial respiratory effect, alleviates chronic neuropathic and cancer pain, offers rapid response in acute depression including suicidal ideation, prevents post-operative depression risk and supports neuroplasticity. Conclusions: Ketamine is a promising drug in anesthesiology and psychiatry, but its long-term safety is not yet determined. Future research should focus on identifying biomarkers that determine treatment response, optimizing dosage, and discovering safer derivatives.
- 6 January 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (1(49))
Open AccessKETAMINE IN PAIN MANAGEMENT AND PSYCHIATRIC TREATMENT: CURRENT KNOWLEDGE AND IMPLICATIONS FOR CLINICAL PRACTICE
Research objectives: Ketamine, a derivative of phencyclidine, is a dissociative anesthetic that is used not only in anesthesia but also in analgesic and psychiatric settings such as perioperative and chronic pain, opioid-induced hyperalgesia and treatment-resistant depression management. With the general population’s prevalence of 2-40% for chronic pain and similar lifetime values for depression, ketamine deserves attention as an alternative to commonly used treatments. This research describes the use of subanesthetic ( 0,3 mg/kg to 0,5 mg/kg) ketamine doses in pain management and psychiatric settings, discusses its safety concerning psychomimetic and physical adverse effects and dependence risk, and suggests future research directions. Methods: Review of literature including peer-reviewed studies, meta-analyses, randomized controlled trials, clinical guidelines, focusing on ketamine pharmacokinetics, anesthetic and antidepressant effects, safety and clinical applications. Findings: Ketamine produces satisfactory short-term pain alleviation and rapid antidepressant action. It is part of multimodal anesthesia protocols as an adjuvant to other local anesthetics, prolonging their effects, and is a safe alternative for analgesia in opioid-tolerant patients. It has many routes of administration, which is used in patients with difficult intravenous access in emergencies. It provides a beneficial respiratory effect, alleviates chronic neuropathic and cancer pain, offers rapid response in acute depression including suicidal ideation, prevents post-operative depression risk and supports neuroplasticity. Conclusions: Ketamine is a promising drug in anesthesiology and psychiatry, but its long-term safety is not yet determined. Future research should focus on identifying biomarkers that determine treatment response, optimizing dosage, and discovering safer derivatives.
- Open Access
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Ocular Rosacea: Beyond the Skin
Background: To the development of rosace contribute factors such as genetic, environmental, and neurovascular causes.. The ocular form affects an estimated prevalence of 10-46% of patients. Symptoms may include redness and tearing of the eyes, foreign body sensation, burning, dryness, itching, photophobia, blurred vision, eyelid margin telangiectasia, and periorbital erythema. Purpose: Ocular rosacea is a long lasting condition that causes persistent inflammation of the eyes and eyelids. The aim of this paper is to organize information on the etiopathogenesis, diagnosis and treatment of this disease. Methods: Comprehensive review of the literature available on PubMed, Google Scholar, Scopus database by searching the keywords “rosacea”, “ocular rosacea”, “ ocular rosacea treatment”, “keratitis”, “dry eye syndroms” Results: Diagnosis requires vigilance because the disease is often confused with other ophthalmological conditions. There are no specific treatment guidelines for ocular rosacea. Managment options depend on the stage of the disease, ranging from conservative treatment based on proper eyelid hygiene and avoidance of triggers in the mildest cases to long-term systemic antibiotic therapy in patients with advanced disease. Conclusions: Ocular rosacea is a disease that is not yet fully understood. Expanding research on this manifestation of rosacea is essential to develop standards for diagnosis and treatment. Collaboration between physicians from multiple specialties in patient care is essential to ensure rapid diagnosis and comprehensive treatment.
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Open AccessOcular Rosacea: Beyond the Skin
Background: To the development of rosace contribute factors such as genetic, environmental, and neurovascular causes.. The ocular form affects an estimated prevalence of 10-46% of patients. Symptoms may include redness and tearing of the eyes, foreign body sensation, burning, dryness, itching, photophobia, blurred vision, eyelid margin telangiectasia, and periorbital erythema. Purpose: Ocular rosacea is a long lasting condition that causes persistent inflammation of the eyes and eyelids. The aim of this paper is to organize information on the etiopathogenesis, diagnosis and treatment of this disease. Methods: Comprehensive review of the literature available on PubMed, Google Scholar, Scopus database by searching the keywords “rosacea”, “ocular rosacea”, “ ocular rosacea treatment”, “keratitis”, “dry eye syndroms” Results: Diagnosis requires vigilance because the disease is often confused with other ophthalmological conditions. There are no specific treatment guidelines for ocular rosacea. Managment options depend on the stage of the disease, ranging from conservative treatment based on proper eyelid hygiene and avoidance of triggers in the mildest cases to long-term systemic antibiotic therapy in patients with advanced disease. Conclusions: Ocular rosacea is a disease that is not yet fully understood. Expanding research on this manifestation of rosacea is essential to develop standards for diagnosis and treatment. Collaboration between physicians from multiple specialties in patient care is essential to ensure rapid diagnosis and comprehensive treatment.
- Open Access
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Ocular Rosacea: Beyond the Skin
Background: To the development of rosace contribute factors such as genetic, environmental, and neurovascular causes.. The ocular form affects an estimated prevalence of 10-46% of patients. Symptoms may include redness and tearing of the eyes, foreign body sensation, burning, dryness, itching, photophobia, blurred vision, eyelid margin telangiectasia, and periorbital erythema. Purpose: Ocular rosacea is a long lasting condition that causes persistent inflammation of the eyes and eyelids. The aim of this paper is to organize information on the etiopathogenesis, diagnosis and treatment of this disease. Methods: Comprehensive review of the literature available on PubMed, Google Scholar, Scopus database by searching the keywords “rosacea”, “ocular rosacea”, “ ocular rosacea treatment”, “keratitis”, “dry eye syndroms” Results: Diagnosis requires vigilance because the disease is often confused with other ophthalmological conditions. There are no specific treatment guidelines for ocular rosacea. Managment options depend on the stage of the disease, ranging from conservative treatment based on proper eyelid hygiene and avoidance of triggers in the mildest cases to long-term systemic antibiotic therapy in patients with advanced disease. Conclusions: Ocular rosacea is a disease that is not yet fully understood. Expanding research on this manifestation of rosacea is essential to develop standards for diagnosis and treatment. Collaboration between physicians from multiple specialties in patient care is essential to ensure rapid diagnosis and comprehensive treatment.
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Open AccessOcular Rosacea: Beyond the Skin
Background: To the development of rosace contribute factors such as genetic, environmental, and neurovascular causes.. The ocular form affects an estimated prevalence of 10-46% of patients. Symptoms may include redness and tearing of the eyes, foreign body sensation, burning, dryness, itching, photophobia, blurred vision, eyelid margin telangiectasia, and periorbital erythema. Purpose: Ocular rosacea is a long lasting condition that causes persistent inflammation of the eyes and eyelids. The aim of this paper is to organize information on the etiopathogenesis, diagnosis and treatment of this disease. Methods: Comprehensive review of the literature available on PubMed, Google Scholar, Scopus database by searching the keywords “rosacea”, “ocular rosacea”, “ ocular rosacea treatment”, “keratitis”, “dry eye syndroms” Results: Diagnosis requires vigilance because the disease is often confused with other ophthalmological conditions. There are no specific treatment guidelines for ocular rosacea. Managment options depend on the stage of the disease, ranging from conservative treatment based on proper eyelid hygiene and avoidance of triggers in the mildest cases to long-term systemic antibiotic therapy in patients with advanced disease. Conclusions: Ocular rosacea is a disease that is not yet fully understood. Expanding research on this manifestation of rosacea is essential to develop standards for diagnosis and treatment. Collaboration between physicians from multiple specialties in patient care is essential to ensure rapid diagnosis and comprehensive treatment.